Graft Rejection Clinical Trial
Official title:
A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation
The current anti-rejection drug regime for kidney transplant recipients in use at the West London Renal & Transplant Centre (WLRaTC) consists of induction therapy with the very potent monoclonal antibody Campath 1-H (Alemtuzumab) followed by long-term maintenance with the Calcineurin inhibitor Tacrolimus The recent development (and licensing in the UK) of an extended-release, once daily formulation of Tacrolimus holds out the promise of simpler drug regimes for our patients. In the context of our current successful use of Tacrolimus monotherapy maintenance after Campath 1-H induction, the extended-release Tacrolimus formulation will enable us to offer a regime where the only long-term immunosuppressive treatment that most of our patients need will be a single drug, taken once a day. The investigators wish to assess the efficacy of such a regime in a structured comparison with our current protocol.
1. Purpose of Study: The current immunosuppressive regime used as anti-rejection therapy after kidney transplantation in the West London Renal & Transplant Centre at Imperial College Healthcare NHS Trust consists of induction therapy with Campath 1-H(Alemtuzumab) and a 1 week course of steroids followed by maintenance mono-therapy with standard-release (twice daily) Tacrolimus (Prograf). This study is designed to compare the costs and outcomes of this regime with one in which extended-release (once daily) Tacrolimus (Advagraf) is used in place of the standard-release Tacrolimus. 2. Study Type: Phase IV 3. Study Design: Prospective, randomised, controlled, open study. Patients will be randomized 1:1 between the standard and extended-release Tacrolimus arms. Study entry will be stratified by live donor vs deceased donor transplants. The total recruitment target is 100 patients (50 standard release/50 extended release). 4. Study Description: Patients will be randomised to receive either Prograf or Advagraf prior to transplantation. Other than through the taking of extra blood samples at the time of routine clinical visits, participants will receive identical in-patient and out-patient management to patients undergoing kidney transplantation under our standard protocol. Patients in the study will be asked to complete a short Health-Related Quality of Life questionnaire (SF-36) before transplantation and at 1 year post transplant. They will also be asked to complete a Medication Adherence Rating Score at 3, 6, and 12 months post-transplant. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00771875 -
Randomized Trial for Mixed Acute Rejection
|
Phase 2 | |
| Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01009619 -
Azithromycin in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT05072951 -
Urine Biomarker for Kidney Transplant Rejection
|
||
| Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Recruiting |
NCT01066689 -
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
|
Phase 3 | |
| Completed |
NCT00251004 -
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
|
Phase 3 | |
| Completed |
NCT00254709 -
Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients
|
Phase 4 | |
| Recruiting |
NCT04851145 -
Mass Spectrometry-based Proteomics in Microvascular Inflammation Diagnosis in Kidney Transplantation.
|
N/A | |
| Completed |
NCT00001984 -
Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
|
Phase 2 | |
| Completed |
NCT04488094 -
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
|
Phase 2 | |
| Not yet recruiting |
NCT03147157 -
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
|
N/A | |
| Completed |
NCT00761787 -
Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
|
N/A | |
| Completed |
NCT00000137 -
Collaborative Corneal Transplantation Studies (CCTS)
|
Phase 3 | |
| Completed |
NCT00266123 -
Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00035555 -
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
|
Phase 2 | |
| Completed |
NCT00001858 -
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
|
||
| Completed |
NCT00895583 -
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00089947 -
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
|
Phase 2 | |
| Enrolling by invitation |
NCT05285878 -
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
|
Phase 2 |